Renaissance Technologies
MBRX icon

Renaissance Technologies’s Moleculin Biotech MBRX Stock Holding History

Renaissance Technologies’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-460
Closed -$19.5K – 3691
2024
Q4 		$19.5K Buy
460
+20
+5% +$1.21K ﹤0.01% 3483
2024
Q3 		$31.2K Buy
+440
New +$31.7K ﹤0.01% 3395
2024
Q1 		– Sell
-346
Closed -$111K – 3924
2023
Q4 		$111K Buy
346
+25
+8% +$5.19K ﹤0.01% 3279
2023
Q3 		$51K Sell
321
-19
-6% -$3.93K ﹤0.01% 3398
2023
Q2 		$74K Buy
340
+88
+35% +$23.2K ﹤0.01% 3533
2023
Q1 		$91K Buy
252
+33
+15% +$14.5K ﹤0.01% 3517
2022
Q4 		$87K Sell
219
-6
-3% -$2.53K ﹤0.01% 3661
2022
Q3 		$90K Sell
225
-10
-4% -$5.79K ﹤0.01% 3628
2022
Q2 		$128K Buy
235
+75
+47% +$43.6K ﹤0.01% 3782
2022
Q1 		$107K Buy
160
+71
+80% +$40.7K ﹤0.01% 3781
2021
Q4 		$62K Buy
+89
New +$78.9K ﹤0.01% 3758
2021
Q1 		– Sell
-422
Closed -$756K – 3550
2020
Q4 		$756K Buy
422
+26
+7% +$46.1K ﹤0.01% 2634
2020
Q3 		$724K Sell
396
-212
-35% -$451K ﹤0.01% 2671
2020
Q2 		$1.32M Buy
608
+46
+8% +$109K ﹤0.01% 2410
2020
Q1 		$770K Buy
562
+114
+25% +$194K ﹤0.01% 2549
2019
Q4 		$922K Buy
448
+32
+8% +$74.9K ﹤0.01% 2673
2019
Q3 		$1.04M Buy
416
+45
+12% +$116K ﹤0.01% 2579
2019
Q2 		$1.04M Buy
371
+301
+430% +$818K ﹤0.01% 2660
2019
Q1 		$127K Buy
70
+52
+289% +$155K ﹤0.01% 3275
2018
Q4 		$43K Buy
+18
New +$51.7K ﹤0.01% 3297

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Renaissance Technologies's MBRX Position: Q1 2025 in Review

Renaissance Technologies sold out of Moleculin Biotech (MBRX) in Q1 2025, closing a stake of 460 shares — an estimated $19.5K sold.

Renaissance Technologies first reported a position in MBRX in Q4 2018 and held it in 20 quarters. The position peaked at $1.32M in Q2 2020. 22 funds tracked by Wall St. Rank hold MBRX as of Q1 2025.

  • Renaissance Technologies reported no remaining Moleculin Biotech position as of Q1 2025 after selling out during the quarter.
  • Renaissance Technologies sold 460 Moleculin Biotech shares in Q1 2025, an estimated $19.5K.
  • Renaissance Technologies first reported a position in Moleculin Biotech in Q4 2018 and held it in 20 quarters.
  • Renaissance Technologies's Moleculin Biotech position peaked at $1.32M in Q2 2020.
  • 22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.